Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 11OTHER 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1NET 1Endocrine 1

Conditions

Ovarian Neoplasms 2Sarcoma, Ewing 1Sarcoma 1Recurrence 1Neuroendocrine Tumors 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Has results × ganitumab × Clear all
NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Dana-Farber Cancer Institute

Phase 2 Terminated
10 enrolled 15 charts
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing

NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 7 charts
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00718523 2016-01-12

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Translational Research in Oncology

Phase 2 Terminated
170 enrolled 20 charts
Gynecologic

Ovarian Neoplasms

NCT00719212 2016-01-11

Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer

Translational Research in Oncology

Phase 2 Completed
61 enrolled 22 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡